A systematic review of randomized trials forÂ theÂ trea is there any light at the end of the tunnel?

Citation Report

#	ARTICLE	IF	CITATIONS
1	AMH for predicting poor ovarian responders in GnRH antagonist cycles. Human Reproduction, 2012, 27, 1876-1877.	0.4	3
2	Treatment strategies in assisted reproduction for the poor responder patient. , 2012, , 162-207.		4
3	Best practices of ASRM and ESHRE: a journey through reproductive medicine. Human Reproduction, 2012, 27, 3365-3379.	0.4	22
4	Reply: AMH for predicting poor ovarian responders in GnRH antagonist cycles. Human Reproduction, 2012, 27, 1877-1877.	0.4	0
5	Reply: The Bologna criteria for poor ovarian response; has the job been accomplished?. Human Reproduction, 2012, 27, 1875-1876.	0.4	5
6	The Bologna criteria for poor ovarian response; has the job been accomplished?. Human Reproduction, 2012, 27, 1874-1875.	0.4	40
7	Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria. Human Reproduction, 2012, 27, 3481-3486.	0.4	104
9	Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis. Reproductive BioMedicine Online, 2012, 25, 450-459.	1.1	50
10	ICSI increases ongoing pregnancy rates in patients with poor response cycle: multivariate analysis of 2819 cycles. Reproductive BioMedicine Online, 2012, 25, 635-641.	1.1	12
11	Cumulative live birth rate after three ovarian stimulation IVF cycles for poor ovarian responders according to the bologna criteria. Journal of Huazhong University of Science and Technology [Medical Sciences], 2013, 33, 418-422.	1.0	17
12	Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem. Fertility and Sterility, 2013, 100, 1270-1276.e3.	0.5	78
13	Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. Human Reproduction, 2013, 28, 1254-1260.	0.4	38
14	Predictors of ovarian response in women treated with corifollitropin alfa for inÂ vitro fertilization/intracytoplasmic sperm injection. Fertility and Sterility, 2013, 100, 430-437.	0.5	52
15	Does the time interval between antimÃ¼llerian hormone serum sampling and initiation of ovarianÂ stimulation affect its predictive ability in inÂ vitro fertilizationâ€"intracytoplasmic spermÂ injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study. Fertility and Sterility, 2013, 100, 438-444.	0.5	24
16	Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: anÂ observational pilot study. Fertility and Sterility, 2013, 99, 422-426.	0.5	41
17	Corifollitropin Î± followed by menotropin for poor ovarian respondersâ€™ trial (COMPORT): a protocol of a multicentre randomised trial. BMJ Open, 2013, 3, e002938.	0.8	11
18	Management of Poor Responders in IVF: Is There Anything New?. BioMed Research International, 2014, 2014, 1-10.	0.9	104
19	The Bologna criteria for the definition of poor ovarian responders: is there a need for revision?. Human Reproduction, 2014, 29, 1842-1845.	0.4	123

#	ARTICLE	IF	CITATIONS
20	Embryo quality in controlled ovarian stimulation for<i>in vitro</i>fertilization in young poor responders. Gynecological Endocrinology, 2014, 30, 657-659.	0.7	7
21	Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reproductive BioMedicine Online, 2014, 29, 684-691.	1.1	230
22	Ala307Thr and Asn680Ser Polymorphisms of<i>FSHR</i>Gene in Human Reproduction Outcomes. Cellular Physiology and Biochemistry, 2014, 34, 1527-1535.	1.1	32
23	Medical Approaches to Ovarian Stimulation for Infertility. , 2014, , 701-733.e8.		2
24	Poor ovarian responders: to meta-analyse or not, that is the question. Human Reproduction, 2014, 29, 634-635.	0.4	10
25	Strategies for Controlled Ovarian Stimulation in the Setting of Ovarian Aging. Seminars in Reproductive Medicine, 2015, 33, 436-448.	0.5	7
26	The Bologna criteria for poor ovarian response: a contemporary critical appraisal. Journal of Ovarian Research, 2015, 8, 76.	1.3	76
27	What Number of Oocytes Is Appropriate for Defining Poor Ovarian Response?. Yonsei Medical Journal, 2015, 56, 482.	0.9	10
28	Live Birth and Cumulative Live Birth Rates in Expected Poor Ovarian Responders Defined by the Bologna Criteria Following IVF/ICSI Treatment. PLoS ONE, 2015, 10, e0119149.	1.1	20
29	Reply: Is it necessary to recognize the sub-optimal responder. Human Reproduction, 2015, 30, dev255.	0.4	1
30	Efficacy and Safety of Pergoveris in Assisted Reproductive Technology—ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment. BMJ Open, 2015, 5, e008297.	0.8	7
31	Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian responders. Gynecological Endocrinology, 2015, 31, 885-890.	0.7	21
32	Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. Fertility and Sterility, 2015, 104, 612-619.e3.	0.5	125
33	A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria. Human Reproduction, 2015, 30, 315-322.	0.4	100
35	Sub-optimal responders following controlled ovarian stimulation: an overlooked group?. Human Reproduction, 2015, 30, 2005-2008.	0.4	82
36	Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders. Human Reproduction, 2015, 30, 2321-2330.	0.4	61
37	450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility, 2015, 104, 1419-1425.	0.5	40
38	Dehydroepiandrosterone administration before IVF in poor responders: a prospective cohort study. Reproductive BioMedicine Online, 2015, 30, 191-196.	1.1	37

#	Article	IF	Citations
39	Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients. International Journal of Women's Health, 2016, Volume 8, 609-615.	1.1	7
40	Morphokinetic Characteristics and Developmental Potential of In Vitro Cultured Embryos from Natural Cycles in Patients with Poor Ovarian Response. BioMed Research International, 2016, 2016, 1-8.	0.9	13
41	A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertility and Sterility, 2016, 105, 1452-1453.	0.5	401
42	Ovarian sensitivity index is a new cost-effective parameter for ovarian responsiveness in an IVF/ICSI cycle. Evidence Based Women S Health Journal, 2016, 6, 80-84.	0.0	0
43	Minimum ovarian stimulation involving combined clomiphene citrate and estradiol treatment for <i>in vitro</i> fertilization of Bolognaâ€criteria poor ovarian responders. Journal of Obstetrics and Gynaecology Research, 2016, 42, 178-183.	0.6	8
44	Younger poor ovarian response women achieved better pregnancy results in the first three IVF cycles. Reproductive BioMedicine Online, 2016, 32, 532-537.	1.1	20
47	Modified natural cycle IVF for poor ovarian responders: rethink before concluding. Human Reproduction, 2016, 31, 221-222.	0.4	9
49	Age is a major prognosticator in extremely low oocyte retrieval cycles. Taiwanese Journal of Obstetrics and Gynecology, 2017, 56, 175-180.	0.5	7
50	Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Human Reproduction, 2017, 32, 544-555.	0.4	53
51	Dehydroepiandrosterone (DHEA) supplementation and IVF outcome in poor responders. Human Fertility, 2017, 20, 80-87.	0.7	13
52	Effect of mid-follicular phase recombinant LH versus urinary HCG supplementation in poor ovarian responders undergoing IVF â€“ a prospective double-blinded randomized study. Reproductive BioMedicine Online, 2017, 34, 258-266.	1.1	24
53	Live birth rates are satisfactory following multiple IVF treatment cycles in poor prognosis patients. Reproductive Biology, 2017, 17, 34-41.	0.9	11
54	Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Human Reproduction, 2017, 32, 2225-2233.	0.4	34
55	Optimal embryo transfer strategy in poor response may include freeze-all. Journal of Assisted Reproduction and Genetics, 2017, 34, 79-87.	1.2	23
56	Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI. In Vivo, 2017, 31, 231-238.	0.6	23
57	Can ovarian double-stimulation in the same menstrual cycle improve IVF outcomes?. Jornal Brasileiro De Reproducao Assistida, 2017, 21, 217-221.	0.3	25
58	What is new in the management of poor ovarian response in IVF?. Current Opinion in Obstetrics and Gynecology, 2018, 30, 155-162.	0.9	90
59	Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertility and Sterility, 2018, 109, 644-664.	0.5	105

#	Article	IF	Citations
60	Does freeze–all policy affect IVF outcome in poor ovarian responders?. Ultrasound in Obstetrics and Gynecology, 2018, 52, 530-534.	0.9	24
61	Individualized controlled ovarian stimulation in expected poor-responders: an update. Reproductive Biology and Endocrinology, 2018, 16, 20.	1.4	66
62	Poor definition of poor-ovarian response results in misleading clinical recommendations. Human Reproduction, 2018, 33, 979-980.	0.4	12
63	Utilization of the Bologna criteria: a promise unfulfilled? A review of published and unpublished/ongoing trials. Fertility and Sterility, 2018, 109, 104-109.e2.	0.5	22
64	Dehydroepiandrosterone supplementation in women undergoing assisted reproductive technology with poor ovarian response. A prospective case-control study. Journal of International Medical Research, 2018, 46, 143-149.	0.4	12
65	Luteal phase ovarian stimulation for poor ovarian responders. Jornal Brasileiro De Reproducao Assistida, 2018, 22, 193-198.	0.3	20
66	The Consultation with the Poor Responder. , 0, , 14-18.		0
67	Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 231, 192-197.	0.5	4
68	Dehydroepiandrosterone (DHEA) supplementation improves in vitro fertilization outcomes of poor ovarian responders, especially in women with low serum concentration of DHEA-S: a retrospective cohort study. Reproductive Biology and Endocrinology, 2018, 16, 90.	1.4	41
69	Double Stimulation in the Same Ovarian Cycle (DuoStim) to Maximize the Number of Oocytes Retrieved From Poor Prognosis Patients: A Multicenter Experience and SWOT Analysis. Frontiers in Endocrinology, 2018, 9, 317.	1.5	104
70	Efficacy of luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist priming protocol in poor responders undergoing <i>in vitro</i> fertilization. Obstetrics and Gynecology Science, 2018, 61, 102.	0.6	9
71	Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria–The Why. Frontiers in Endocrinology, 2018, 9, 461.	1.5	122
72	Luteal Phase Ovarian Stimulation May Improve Oocyte Retrieval and Oocyte Quality in Poor Ovarian Responders Undergoing In Vitro Fertilization: Preliminary Results from a Single-Center Prospective Pilot Study. Advances in Therapy, 2018, 35, 847-856.	1.3	29
73	Medical Approaches to Ovarian Stimulation for Infertility. , 2019, , 743-778.e7.		3
74	Cumulative Live Birth Rates in Low Prognosis Patients According to the POSEIDON Criteria: An Analysis of 26,697 Cycles of in vitro Fertilization/Intracytoplasmic Sperm Injection. Frontiers in Endocrinology, 2019, 10, 642.	1.5	38
75	Management Strategies for POSEIDON's Group 1. Frontiers in Endocrinology, 2019, 10, 679.	1.5	15
76	Management Strategies for POSEIDON Groups 3 and 4. Frontiers in Endocrinology, 2019, 10, 614.	1.5	43
77	Dual stimulation using corifollitropin alfa in 54 Bologna criteria poor ovarian responders – a case series. Reproductive BioMedicine Online, 2019, 38, 677-682.	1.1	39

#	ARTICLE	IF	CITATIONS
78	Novel approaches for diagnosis and management of low prognosis patients in assisted reproductive technology: the POSEIDON concept. Panminerva Medica, 2019, 61, 24-29.	0.2	46
79	Ovarian Reserve Markers to Identify Poor Responders in the Context of Poseidon Classification. Frontiers in Endocrinology, 2019, 10, 281.	1.5	59
80	Understanding Follicular Output Rate (FORT) and its Implications for POSEIDON Criteria. Frontiers in Endocrinology, 2019, 10, 246.	1.5	28
81	Cumulative Live Birth Rates Following Stimulation With Corifollitropin Alfa Compared With hp-hMG in a GnRH Antagonist Protocol in Poor Ovarian Responders. Frontiers in Endocrinology, 2019, 10, 175.	1.5	10
82	The Use of LH Supplements to Improve the Response to Ovarian Stimulation. , 2019, , 167-181.		0
83	Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate. Reproductive BioMedicine Online, 2019, 38, 908-915.	1.1	59
84	The Effect of Growth Hormone on the Clinical Outcomes of Poor Ovarian Reserve Patients Undergoing in vitro Fertilization/Intracytoplasmic Sperm Injection Treatment: A Retrospective Study Based on POSEIDON Criteria. Frontiers in Endocrinology, 2019, 10, 775.	1.5	18
85	Dehydroepiandrosterone Supplementation Improves the Outcomes of in vitro Fertilization Cycles in Older Patients With Diminished Ovarian Reserve. Frontiers in Endocrinology, 2019, 10, 800.	1.5	17
86	Bologna criteria are predictive for ovarian response and live birth in subsequent ovarian stimulation cycles. Archives of Gynecology and Obstetrics, 2019, 299, 571-577.	0.8	9
87	Pituitary suppression protocol among Bologna poor responders undergoing ovarian stimulation using corifollitropin alfa: does it play any role?. Reproductive BioMedicine Online, 2019, 38, 1010-1017.	1.1	10
88	Risk factors for inadequate response to ovarian stimulation in assisted reproduction cycles: systematic review. Journal of Assisted Reproduction and Genetics, 2019, 36, 19-28.	1.2	12
89	Luteal phase after conventional stimulation in the same ovarian cycle might improve the management of poor responder patients fulfilling the Bologna criteria: a case series. Fertility and Sterility, 2020, 113, 121-130.	0.5	46
90	Corifollitropin alfa for poor responders patients, a prospective randomized study. Reproductive Biology and Endocrinology, 2020, 18, 67.	1.4	6
91	How effective are the non-conventional ovarian stimulation protocols in ART? A systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics, 2020, 37, 2913-2928.	1.2	14
92	Comparative Effectiveness of Mild or Conventional GnRH-Antagonist Protocols for Ovarian Stimulation in Poor Responders (Poseidon Group 4). Frontiers in Reproductive Health, 2020, 2, .	0.6	0
93	Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept. Therapeutic Advances in Reproductive Health, 2020, 14, 263349412094148.	1.3	27
94	The continuum of ovarian response leading to BIRTH, a real world study of ART in Spain. Fertility Research and Practice, 2020, 6, 13.	4.1	6
95	SAY NO to mild ovarian stimulation for all poor responders: it is time to realize that not all poor responders are the same. Human Reproduction, 2020, 35, 1964-1971.	0.4	15

#	Article	IF	Citations
96	The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment. Diagnostics, 2020, 10, 687.	1.3	12
97	Effect of acupuncture on women with poor ovarian response: a study protocol for a multicenter randomized controlled trial. Trials, 2020, 21, 775.	0.7	1
98	The addition of clomiphene citrate to ovarian stimulation protocols for poor responders. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 251, 136-140.	0.5	7
99	Efficacy and safety of Dingkun pill for female infertility patients with low prognosis undergoing in vitro fertilization-embryo transfer: study protocol for a multicenter, double-blind, randomized, placebo-controlled trial. Trials, 2020, 21, 550.	0.7	4
100	Management Strategies for POSEIDON Group 2. Frontiers in Endocrinology, 2020, 11, 105.	1.5	10
101	Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations. International Journal of Molecular Sciences, 2020, 21, 2110.	1.8	34
102	Assessing the practice of LuPOR for poor responders: a prospective study evaluating follicular fluid cfDNA levels during natural IVF cycles. Journal of Assisted Reproduction and Genetics, 2020, 37, 1183-1194.	1.2	8
103	Dual-trigger improves the outcomes of in vitro fertilization cycles in older patients with diminished ovarian reserve: A retrospective cohort study. PLoS ONE, 2020, 15, e0235707.	1.1	24
104	Growth Hormone Supplementation May Not Improve Live Birth Rate in Poor Responders. Frontiers in Endocrinology, 2020, 11, 1.	1.5	140
105	Commentary: Management Strategies for POSEIDON Groups 3 and 4. Frontiers in Endocrinology, 2019, 10, 920.	1.5	2
106	Heterogeneity Among Poor Ovarian Responders According to Bologna Criteria Results in Diverging Cumulative Live Birth Rates. Frontiers in Endocrinology, 2020, 11, 208.	1.5	9
107	Effect of recombinant LH supplementation on cumulative live birth rate compared with FSH alone in poor ovarian responders: a large, real-world study. Reproductive BioMedicine Online, 2021, 42, 546-554.	1.1	11
108	Efficacy of the delayed start antagonist protocol for controlled ovarian stimulation in Bologna poor ovarian responders: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 2021, 303, 347-362.	0.8	6
109	Patients with higher anti-Müllerian hormone levels from POSEIDON group 4 benefit from GnRH-agonist long protocol: A retrospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 257, 88-94.	0.5	7
110	Investigating apoptotic, inflammatory, and growth markers in poor responders undergoing natural *in vitro* fertilization cycles: a pilot study. Annals of the New York Academy of Sciences, 2021, 1489, 78-90.	1.8	0
111	Human Menopausal Gonadotropin Commenced on Early Follicular Period Increases Live Birth Rates in POSEIDON Group 3 and 4 Poor Responders. Reproductive Sciences, 2021, 28, 488-494.	1.1	5
112	Type and dose of gonadotropins in poor ovarian responders: does it matter?. Therapeutic Advances in Reproductive Health, 2021, 15, 263349412110242.	1.3	2
113	The POSEIDON stratification - moving from poor ovarian response to low prognosis. Jornal Brasileiro De Reproducao Assistida, 2021, 25, 282-292.	0.3	6

#	Article	IF	Citations
114	Reporting on the Role of miRNAs and Affected Pathways on the Molecular Backbone of Ovarian Insufficiency: A Systematic Review and Critical Analysis Mapping of Future Research. Frontiers in Cell and Developmental Biology, 2020, 8, 590106.	1.8	2
115	Double or dual stimulation in poor ovarian responders: where do we stand?. Therapeutic Advances in Reproductive Health, 2021, 15, 263349412110241.	1.3	10
116	Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines. Frontiers in Endocrinology, 2021, 12, 587051.	1.5	14
117	Do follicular fluid advanced glycation end products levels affect the ovarian response in unexplained infertility?. Gynecological Endocrinology, 2021, 37, 802-806.	0.7	2
118	Endometrial scratching for poor responders based on the Bologna criteria in ICSI fresh embryo transfer cycles: a preliminary retrospective cohort study. Journal of the Turkish German Gynecology Association, 2021, 22, 47-52.	0.2	1
119	Machine-intelligence for developing a potent signature to predict ovarian response to tailor assisted reproduction technology. Aging, 2021, 13, 17137-17154.	1.4	12
120	The association between thrombophilic genes alterations and poor ovarian response in infertile women: a retrospective case-control study. Journal of Obstetrics and Gynaecology, 2021, , 1-6.	0.4	1
121	The Role of Traditional Chinese Formula Ding-Kun Pill (DKP) in Expected Poor Ovarian Response Women (POSEIDON Group 4) Undergoing In Vitro Fertilization-Embryo Transfer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Frontiers in Endocrinology, 2021, 12, 675997.	1.5	14
122	Comparison of Dydrogesterone and Medroxyprogesterone in the Progestin-Primed Ovarian Stimulation Protocol for Patients With Poor Ovarian Response. Frontiers in Endocrinology, 2021, 12, 708704.	1.5	10
123	Comparison of the Cumulative Live Birth Rates of Progestin-Primed Ovarian Stimulation and Flexible GnRH Antagonist Protocols in Patients With Low Prognosis. Frontiers in Endocrinology, 2021, 12, 705264.	1.5	21
124	The Use of Androgen Priming in Women with Reduced Ovarian Reserve Undergoing Assisted Reproductive Technology. Seminars in Reproductive Medicine, 2021, 39, 207-219.	0.5	1
125	Live birth rates in different subgroups of poor ovarian responders according to Bologna and POSEIDON group classification criteria. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 102169.	0.6	1
126	Expression of genes that regulate follicle development and maturation during ovarian stimulation in poor responders. Reproductive BioMedicine Online, 2021, 42, 248-259.	1.1	4
127	Fresh and cumulative live birth rates in mild versus conventional stimulation for IVF cycles in poor ovarian responders: a systematic review and meta-analysis. Human Reproduction Open, 2021, 2021, hoaa066.	2.3	14
128	Meta-analysis of GnRH-antagonists versus GnRH-agonists in poor responder protocols. Archives of Gynecology and Obstetrics, 2021, 304, 547-557.	0.8	6
129	Live birth rates of low prognosis patients according to POSEIDON criteria; A retrospective cohort study. Journal of Gynecology Obstetrics and Human Reproduction, 2020, 49, 101817.	0.6	6
130	Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Human Reproduction Update, 2020, 26, 247-263.	5.2	120
131	Association of Follicle-Stimulating Hormone Receptor Polymorphisms with Ovarian Response in Chinese Women: A Prospective Clinical Study. PLoS ONE, 2013, 8, e78138.	1.1	43

#	ARTICLE	IF	CITATIONS
132	Effect of Dehydroepiandrosterone Administration in Patients with Poor Ovarian Response According to the Bologna Criteria. PLoS ONE, 2014, 9, e99858.	1.1	35
133	Androgens and ovarian function: translation from basic discovery research to clinical impact. Journal of Endocrinology, 2019, 242, R23-R50.	1.2	64
134	Morphological evaluation of human oocytes in IVF practice (a review). Russian Journal of Human Reproduction, 2017, 23, 54.	0.1	1
135	Efficacies of different ovarian hyperstimulation protocols in poor ovarian responders classified by the POSEIDON criteria. Aging, 2020, 12, 9354-9364.	1.4	18
136	Estradiol Pretreatment in an Ultrashort GnRH Combined with a GnRH Antagonist Protocol in A Cohort of Poor Responders Undergoing IVF/ICSI: A Case-control Study. In Vivo, 2016, 30, 945-950.	0.6	7
137	Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT. International Journal of Reproductive BioMedicine, 2017, 15, 101-108.	0.5	23
138	Effective treatment protocol for poor ovarian response: A systematic review and meta-analysis. Journal of Human Reproductive Sciences, 2016, 9, 70.	0.4	49
139	Comparison of microdose GnRH agonist protocol with GnRH antagonist / letrazole protocol in patients with poor ovarian response. TaˆšÂºrk Jinekoloji Ve Obstetrik Dernei Dergisi, 2013, 10, 132-137.	0.3	4
140	The Challenge of Improving IVF Results in Normogonadotrophic (Unexpected) Young Poor Ovarian Responders: The Predictive Value of a Flexible Treatment Protocol Based on the â€œBiophysical Profile of the Uterusâ€. Open Journal of Obstetrics and Gynecology, 2015, 05, 654-664.	0.1	1
144	Role of Metalloproteinases in the Pathogenesis of Unexpected Poor Ovarian Response with a Possible Genetic Predisposition. International Journal of Infertility and Fetal Medicine, 2017, 8, 5-11.	0.0	0
145	Comparison of corifollitropin alfa and daily recombinant follicle-stimulating hormone in poor responder patients undergoing in vitro fertilization cycles. TaˆšÂºrk Jinekoloji Ve Obstetrik Dernei Dergisi, 2017, 14, 199-202.	0.3	0
148	The investigation of the relationship between biofilm-forming properties of clinical strains of p.aeruginosa and their sensitivity to antiseptic medicines. Reports of Vinnytsia National Medical University, 2018, 22, 403-406.	0.0	2
149	A prospective and retrospective analysis of POSEIDON stratification to predict low prognosis patients during ART cycles in Indian population. Fertility Science and Research, 2019, 6, 109.	0.1	0
150	Comparison of the effectiveness of various stimulation protocols in patients with reduced ovarian reserve. Russian Journal of Human Reproduction, 2019, 25, 91.	0.1	1
151	Assisted reproductive technology outcome in poor responders classified by patient-oriented strategies encompassing individualized oocyte number stratification. The Onco Fertility Journal, 2019, 2, 27.	0.3	0
154	Outcomes in poor responders treated with in vitro fertilization/intracytoplasmic sperm injection according to bologna criteria. Reproductive Endocrinology, 2019, .	0.0	0
155	Assisted Reproductive Technologies. Endocrinology, 2020, , 263-284.	0.1	1
156	Assisted Reproductive Technologies. Endocrinology, 2020, , 1-22.	0.1	0

#	ARTICLE	IF	CITATIONS
157	Ð•Ð¢ÐžÐ¡Ð¡ÐšÐ¢˜Ð'ÐÐ˜Ð™ ÐÐÐÐ›Ð†Ð— Ð•Ð•ÐšÐ¢˜Ð'ÐÐžÐ¡Ð¢† ÐŸÐžÐ"ÐÐÐœ Ð"ÐžÐŸÐžÐœÐ†Ð».ÐÐ˜Ð¥ ÐÐ•ÐŸÐžÐž...		
158	Evidence-based reproductive medicine: a critical appraisal. Facts, Views & Vision in ObGyn, 2013, 5, 233-40.	0.5	2
159	Comparison of different ovarian hyperstimulation protocols efficacy in poor ovarian responders according to the Bologna criteria. International Journal of Clinical and Experimental Medicine, 2014, 7, 1128-34.	1.3	22
160	Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT. International Journal of Reproductive BioMedicine, 2017, 15, 101-108.	0.5	15
161	Ovarian Sensitivity Index (OSI): Validating the Use of a Marker for Ovarian Responsiveness in IVF. Journal of Reproduction and Infertility, 2019, 20, 83-88.	1.0	7
162	Effect of dual trigger on reproductive outcome in low responders: a systematic PRISMA review and meta-analysis. Gynecological Endocrinology, 2022, 38, 213-221.	0.7	3
163	Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria. Frontiers in Endocrinology, 2021, 12, 790160.	1.5	7
164	Effectiveness of recombinant luteinizing hormone/human menopausal gonadotropin/letrozole as additives to recombinant follicle-stimulating hormone in women with poor ovarian reserve undergoing controlled ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection. Fertility Science and Research, 2021, 8, 166.	0.1	0
165	POSEIDON 1 and 2: Probable Causes and Proposed Treatment Strategies? An Evidence-based Update. International Journal of Infertility and Fetal Medicine, 2022, 13, 23-27.	0.0	0
166	Cholesterol uptake or trafficking, steroid biosynthesis, and gonadotropin responsiveness are defective in young poor responders. Fertility and Sterility, 2022, 117, 1069-1080.	0.5	9
167	Mild/moderate versus full stimulation. Fertility and Sterility, 2022, 117, 664-668.	0.5	4
168	Effect of dehydroepiandrosterone administration before inÂvitro fertilization on the live birth rate in poor ovarian responders according to the Bologna criteria: A randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, , .	1.1	7
169	Ovarian Stimulation in Poor Responders. , 2022, , 101-108.		0
176	Development of a predictive model for luteal phase oocyte retrieval in poor responders undergoing natural cycle IVF. Scientific Reports, 2022, 12, 7695.	1.6	2
177	Low Oocyte Maturity Rate and Asynchronous Follicle Development: Other Unnoticed Groups in the Bologna Criteria for Poor Responders?. Ä°stanbul Medical Journal:, 2022, 23, 216-219.	0.1	0
178	Clinical predictors of embryo quality among women of advanced age receiving intracytoplasmic sperm injection cycles in Malaysia: A cohort study. International Journal of Reproductive BioMedicine, 0, , 581-590.	0.5	0
179	Predicting IVF outcome in poor ovarian responders. BMC Women's Health, 2022, 22, .	0.8	2
180	Researching the Phenomenon of Poor Ovarian Responders and Management Strategies in IVF: A Narrative Review. Acta Medica Academica, 2022, 51, 108-122.	0.3	0

#	ARTICLE	IF	CITATIONS
181	Effect of Coenzyme Q10 and transcutaneous electrical acupoint stimulation in assisted reproductive technology: a retrospective controlled study. Reproductive Biology and Endocrinology, 2022, 20, .	1.4	3
182	Follicular fluid biomarkers for prediction of human IVF outcome in women with poor ovarian response. Middle East Fertility Society Journal, 2023, 28, .	0.5	0
183	Development and validation of a live birth prediction model for expected poor ovarian response patients during IVF/ICSI. Frontiers in Endocrinology, 0, 14, .	1.5	4
184	Factors Influencing Follicular Output Rate and Follicle-to-Oocyte Index in POSEIDON-Defined Low-Prognosis Women in Vietnam: A Cross-Sectional Study. International Journal of Women's Health, 0, Volume 15, 523-532.	1.1	0
185	Systematic review of acupuncture to improve ovarian function in women with poor ovarian response. Frontiers in Endocrinology, 0, 14, .	1.5	3
186	Causal inference indicates that poor responders have similar outcomes with the antagonist protocol compared with flare. Fertility and Sterility, 2023, 120, 289-296.	0.5	2
191	Maximizing fertility outcomes in poor ovarian response patients. , 2024, , 285-294.		0